dalfopristin

01/01/2004 - "/dalfopristin is administered at 7.5 mg/kg every 8-12 hours, depending upon the severity of infection. "
12/01/2000 - "Quinipristin-dalfopristin and linezolid are 2 new approved antimicrobials for the treatment of recalcitrant infections caused byVRE. "
05/01/1997 - "This result emphasizes the importance of the constant presence of dalfopristin at the site of infection to ensure synergism with quinupristin."
08/01/1999 - "New antibiotics for gram positive infections: linezolid and combination quinapristin/dalfopristin."
10/01/2000 - "Rhône-Poulenc Rorer (RPR) developed Synercid (RP-59500), an injectable synergistic combination of quinupristin and dalfopristin as a treatment for a variety of infections caused by Gram-positive anaerobic bacteria. "

05/01/1998 - "Staphylococcus epidermidis endocarditis treated with RP 59500 (quinapristin/dalfopristin)."
05/01/1997 - "faecium on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis may be related to the reduced diffusion of dalfopristin compared with that of quinupristin into cardiac vegetations that we previously reported. "
03/01/1994 - "We evaluated the in vivo activity and the diffusion of radiolabelled RP 57669 (RPI) and RP 54476 (RPII), the two components of the injectable streptogramin RP 59500, alone or in combination, in aortic vegetations from experimental endocarditis in rabbits. "

12/09/1996 - "Four of the 6 bacteremia cases were central-line related and resolved with line removal alone; 1 was treated with a combination product of quinupristin and dalfopristin (Synercid) and 1 had persistent bacteremia in the presence of a ventriculoperitoneal shunt. "

11/01/2010 - "Potential parenteral agents for the treatment of pyelonephritis and complicated UTIs caused by MDR-Enterococcus include daptomycin, linezolid, and quinipristin-dalfopristin. "

05/01/2007 - "To compare pharmacodynamic indices and minimal inhibitory concentrations for vancomycin, gatifloxacin, moxifloxacin, linezolid, and combined quinupristin and dalfopristin for historic and current human coagulase-negative staphylococcus (CoNS) endophthalmitis isolates. "